Australia - engleză - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - amoxycillin as amoxycillin trihydrate - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 50.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - antibiotics - oral, parenteral | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | hypermotility | infected wounds | infections | lactating | mastitis | protozoal infections | pyometra | salmonellosis | sinusitis | systemic bacterial infection

Malaezia - engleză - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

y.s.p. industries (m) sdn bhd - amoxicillin (as trihydrate); clavulanic acid (as potassium) -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 286.96 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 573.921 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; colloidal anhydrous silica; sodium lauryl sulfate; gelatin; croscarmellose sodium; iron oxide black; microcrystalline cellulose; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, non-penicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n.gonorrhoeae (non-penicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml;  ; potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage);  ;   - powder for oral suspension - 125mg,31.25mg/5ml - active: amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml   potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg - film coated tablet - 250mg/125mg - active: amoxicillin trihydrate 287mg equivalent to amoxycillin 250 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg   excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml;  ; potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage);  ;   - powder for oral suspension - 250mg, 62.5mg/5ml - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml   potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Canada - engleză - Health Canada

apotex inc - amoxicillin (amoxicillin trihydrate); clavulanic acid (clavulanate potassium) - powder for suspension - 400mg; 57mg - amoxicillin (amoxicillin trihydrate) 400mg; clavulanic acid (clavulanate potassium) 57mg - aminopenicillins

Canada - engleză - Health Canada

pro doc limitee - amoxicillin (amoxicillin trihydrate); clavulanic acid (clavulanate potassium) - tablet - 250mg; 125mg - amoxicillin (amoxicillin trihydrate) 250mg; clavulanic acid (clavulanate potassium) 125mg